Drugs / BNT162b4
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05541861 | Nov 2022 → Nov 2024 | COVID-19 | BioNTech SE | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BNT162b4 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05541861 ↗ |
| Modality | Messenger RNA (mRNA) | “BNT162b4, an mRNA vaccine component” PMID 37164012 ↗ Apr 2023 |
| Route | Intramuscular | “administered as intramuscular injection.” NCT05541861 ↗ |